CERo Therapeutics Holdings, Inc.
CERO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $0 | $10 | $9 |
| G&A Expenses | $9 | $0 | $2 | $2 |
| SG&A Expenses | $9 | $3 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $3 | $1 | $0 |
| Other Operating Expenses | $0 | $0 | -$10 | -$11 |
| Operating Expenses | $15 | $3 | $3 | $0 |
| Operating Income | -$15 | -$3 | -$3 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8 | $0 | $3 | -$0 |
| Pre-Tax Income | -$8 | -$2 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $1 | -$0 |
| Net Income | -$8 | -$0 | -$1 | -$0 |
| % Margin | – | – | – | – |
| EPS | -6.87 | -2,497.2 | -19.73 | -2.75 |
| % Growth | 99.7% | -12,556.9% | -617.5% | – |
| EPS Diluted | -6.87 | -2,497.2 | -19.73 | -2.75 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $3 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $3 | $1 |
| EBITDA | -$7 | -$2 | -$0 | $0 |
| % Margin | – | – | – | – |